ArticleAsian Pacific journal of cancer prevention : APJCP2025
Evaluation of CD20-Positive B Cells in Libyan Lymphoma Patients Following Rituximab Treatment.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo monitor the depletion of CD20-positive B cells in Libyan lymphoma patients treated with Rituximab using flow cytometry.
methodsPeripheral blood samples were collected from 25 newly diagnosed Libyan patients with histologically confirmed CD20+ B-cell non-Hodgkin's lymphoma, receiving Rituximab at the Oncology Departments of Tripoli Medical Center and the National Cancer Institute, Sabratha. Patients received intravenous Rituximab (375 mg/m²) combined with CHOP chemotherapy monthly for up to seven months, except one patient treated weekly for six weeks. Flow cytometry using CD19 and CD20 markers was performed on blood samples collected monthly or weekly post-infusion, employing BD TruCOUNT™ tubes and the Lyse No Wash method for accurate quantification of B cells.
resultsOf the 25 patients, 24 (96%) showed complete depletion of CD19+ and CD20+ B cells by the seventh month of Rituximab treatment. Three out of five patients assessed at two months had complete depletion, while two showed a gradual decline. One patient (4%) remained resistant, with B cell counts exceeding 100 cells/μL up to the seventh month. Weekly monitoring in a single patient showed full B cell depletion by week four. Rituximab had no effect on CD3+ T cells, confirming its specificity.
conclusionThis study presents flow cytometry-based assessment of Rituximab efficacy in Libyan B cell lymphoma patients, providing novel population-specific data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.